Artificial Lipid Droplet Preparation for Pure Composition Analysis

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

The formation mechanism and dynamic changes of lipid droplets are difficult to study due to the complexity of their composition and interaction with other cellular organelles, and there is a lack of comprehensive understanding of lipid droplets, which interferes with dissecting their regulatory mechanisms.

Innovation Solution

A preparation method for adiposomes consisting of neutral lipids and a monolayer phospholipid membrane is developed, involving vortexing and a two-step purification process using specific centrifugation parameters to isolate adiposomes, which are then used to create artificial lipid droplets by recruiting resident and functional proteins.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Measurement precision

If isolation and purification of lipid droplets is performed to study their composition, then protein and lipid composition can be analyzed, but the isolated lipid droplets contain fragments of endoplasmic reticulum, mitochondria, and other cellular organelles

Engineering Contradiction:
Improvecomposition analysis accuracyVSAvoidpurity of isolated lipid droplets
Core Design Contradiction:
Measurement precisionVSReliability

Solution Approach 1:

The patent creates artificial lipid droplets (adiposomes) that copy the essential structural features of natural lipid droplets (neutral lipid core surrounded by monolayer phospholipid membrane and proteins) without containing contaminating cellular organelles. This allows studying lipid droplet composition and mechanisms in a purified system that accurately represents natural lipid droplet structure and function

Inventive Principle:
Principle #26Copying

2Device complexity

If artificial lipid droplets are prepared to simplify the system, then the complexity of composition and interactions is reduced, but the structure and composition must closely resemble natural lipid droplets

Engineering Contradiction:
Improvesystem complexityVSAvoidstructural fidelity to natural lipid droplets
Core Design Contradiction:
Device complexityVSManufacturing precision

Solution Approach 1:

The patent segments the lipid droplet system into essential functional components (neutral lipids, phospholipids, and specific proteins) and reassembles them in a controlled manner to form artificial lipid droplets. This segmentation allows simplification of the system while maintaining the critical structural and functional features of natural lipid droplets

Inventive Principle:
Principle #1Segmentation

Solution Approach 2:

The patent uses composite materials comprising neutral lipids, phospholipids, and proteins in specific combinations to create artificial lipid droplets that mimic natural structures. The composite nature of these materials allows precise control over structural fidelity while simplifying the overall system

Inventive Principle:
Principle #40Composite materials

3Reliability

If a two-step purification process is used to isolate adiposomes, then adiposomes can be obtained from the upper liquid phase, but multiple centrifugation steps are required

Engineering Contradiction:
Improveisolation success rateVSAvoidpurification time
Core Design Contradiction:
ReliabilityVSLoss of time

Solution Approach 1:

The patent performs preliminary vortexing and mixing of phospholipids and neutral lipids before centrifugation to ensure proper formation of adiposomes. This preliminary action optimizes the structure and distribution of components, enabling more efficient separation in subsequent centrifugation steps and reducing the number of purification cycles needed

Inventive Principle:
Principle #10Preliminary action

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The method allows for the study of lipid droplets in vitro and provides a drug carrier system, enabling the use of adiposomes as drug carriers for treating conditions like Type II diabetes and metabolic disorders.

Implementation Method 1

a1) vortexing phospholipid and neutral lipids in a buffer to enable a reaction between both

Methodology Applied
Scientific EffectVortexing:

Implementation Method 2

performing centrifugation, collecting an upper liquid phase

Methodology Applied
Scientific EffectCentrifugation: Centrifugal Separation

Implementation Method 3

layering the mixture and collecting an upper liquid phase

Methodology Applied
Scientific EffectDensity gradient: Density Gradient

Data Source

PatentEP3395329B1Preparation method of lipid bodies, and use thereof
Publication Date: 2026.04.15 WECARELIFE BIOTECH CO LTD
  • EP3395329B1 patent drawingFigure 1A~2C
  • EP3395329B1 patent drawingFigure 2D~3D
  • EP3395329B1 patent drawingFigure 3E~5B

AI summary

A preparation method of adiposomes, and use thereof. Particularly, provided is a method for preparing adiposomes consisting of neutral lipids and a monolayer phospholipid membrane, comprising the following steps: a1) vortexing phospholipid and neutral lipids in a buffer to enable the reaction between both, then performing centrifugation and collecting an upper liquid phase; a2) performing purification on the upper liquid phase obtained in the step a1) for twice or more, wherein the process of each purification is: uniformly mixing the upper liquid phase with the buffer, then layering the mixture, and collecting an upper liquid phase; and a3) uniformly mixing the upper liquid phase obtained in step a2) with the buffer, layering the mixture, and collecting a lower liquid phase in which the adiposomes are contained. For the adiposomes prepared by the method, one or more resident proteins and/or functional proteins can be recruited to obtain artificial lipid droplets, and one or more apolipoproteins can be recruited to obtain artificial lipoproteins; and they all play important roles in preparing drugs and/or drug carriers.